TBL1XR1 in physiological and pathological states

Area of Science:

• Molecular Biology
• Genetics
• Oncology

Background:

• Transducin (beta)-like 1X related protein 1 (TBL1XR1) is a key component of nuclear receptor corepressor (NCoR) and silencing mediator of retinoic acid and thyroid hormone receptors (SMRT) complexes.
• TBL1XR1 is crucial for transcriptional repression by unliganded nuclear receptors and other transcription factors, but can also activate transcription by recruiting the proteasome complex.

Purpose of the Study:

• To explore the multifaceted roles of TBL1XR1 in gene regulation and its implications in human diseases.
• To investigate the involvement of TBL1XR1 in cancer development, progression, and therapeutic strategies.

Main Methods:

• Literature review of TBL1XR1's function in transcriptional regulation.
• Analysis of studies linking TBL1XR1 mutations and alterations to intellectual disability and various cancers.
• Examination of pre-clinical data on targeting TBL1XR1 for cancer therapy.

Main Results:

• TBL1XR1 is essential for transcriptional repression and can function as an activator by modulating corepressor/coactivator exchange.
• Germline and recurrent mutations in TBL1XR1 are associated with intellectual disability.
• TBL1XR1 upregulation correlates with advanced tumor stage, metastasis, and poor prognosis in solid tumors, and its loss confers glucocorticoid resistance in B-lymphoblastic leukemia.

Conclusions:

• TBL1XR1 is a critical regulator of gene transcription with significant roles in both normal cellular processes and disease pathogenesis.
• Genomic alterations of TBL1XR1 are implicated in tumorigenesis, though mechanisms require further elucidation.
• Targeting TBL1XR1 interactions, such as with beta-catenin, presents a potential therapeutic avenue for cancers like acute myeloid leukemia (AML).